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Background: The A10 and A7r5 cell lines derived from the thoracic aorta of embryonic rat are widely used as
models of non-differentiated, neonatal and neointimal vascular smooth muscle cells in culture. The recent discovery
of resident multipotent vascular stem cells within the vessel wall has necessitated the identity and origin of these
vascular cells be revisited. In this context, we examined A10 and A7r5 cell lines to establish the similarities and
differences between these cell lines and multipotent vascular stem cells isolated from adult rat aortas by determining their
differentiation state, stem cell marker expression and their multipotency potential in vitro.
Methods: Vascular smooth muscle cell differentiation markers (alpha-actin, myosin heavy chain, calponin) and stem cell
marker expression (Sox10, Sox17 and S100β) were assessed using immunocytochemistry, confocal microscopy, FACS
analysis and real-time quantitative PCR.
Results: Both A10 and A7r5 expressed vascular smooth muscle differentiation, markers, smooth muscle alpha − actin,
smooth muscle myosin heavy chain and calponin. In parallel analysis, multipotent vascular stem cells isolated from rat
aortic explants were immunocytochemically myosin heavy chain negative but positive for the neural stem cell markers
Sox10+, a neural crest marker, Sox17+ the endoderm marker, and the glia marker, S100β+. This multipotent vascular stem
cell marker profile was detected in both embryonic vascular cell lines in addition to the adventitial progenitor stem cell
marker, stem cell antigen-1, Sca1+. Serum deprivation resulted in a significant increase in stem cell and smooth muscle cell
differentiation marker expression, when compared to serum treated cells. Both cell types exhibited weak multipotency
following adipocyte inductive stimulation. Moreover, Notch signaling blockade following γ-secretase inhibition with DAPT
enhanced the expression of both vascular smooth muscle and stem cell markers.
Conclusions: We conclude that A10 and A7r5 cells share similar neural stem cell markers to both multipotent
vascular stem cells and adventitial progenitors that are indicative of neointimal stem-derived smooth muscle
cells. This may have important implications for their use in examining vascular contractile and proliferative
phenotypes in vitro.Introduction
The arterial blood vessel is comprised of three distinct
layers; an innermost monolayer of endothelial cells, a
medial layer composed primarily of vascular smooth
muscle cells [vSMCs] [1-3] and some multipotent vascu-
lar stem cells [MVSCs] [1,4,5], and an outer adventitial
layer of fibroblast cells and some vSMC-related stem cell* Correspondence: paul.cahill@dcu.ie
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unless otherwise stated.antigen-1 (Sca1+) positive progenitor cells [6,7]. The
medial vSMCs in the vessel wall are not terminally dif-
ferentiated but can undergo “phenotypic switching” fol-
lowing vascular injury [8,9]. In a similar manner, vSMCs
in culture are thought to be ‘phenotypically modulated’
[10,11,3]. These ‘contractile’ cells initially express markers
for SMC differentiation such as smooth muscle α-actin
(SMA), smooth muscle myosin heavy chain (SM-MHC),
calponin (CNN1) and SM-22α. However, proliferating
vSMC display the characteristics of de-differentiated
vSMCs in that they have minimal expression of SMCal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cultured on a silicone substrate [12]. Moreover, proliferat-
ing ‘synthetic’ vSMC can be converted back or ‘modulated’
to a more mature phenotype by placing the cells in quies-
cent media to selectively increase in the expression of the
SMC differentiation markers [12,13].
Original studies in canine carotid arteries suggested
that ‘neointimal modulated proliferative SMC’ were not
derived from differentiated SMC but instead formed
from a myosin negative type II medial SMC cell [14]. Re-
cent lineage tracing studies in vivo using SM-MHC
as a marker suggest that SM-MHC− negative resident
multipotent vascular stem cells [MVSCs], and not de-
differentiated vSMCs, repopulate the neointima follow-
ing vascular injury and proliferate and differentiate into
vSMCs [5,15]. Moreover, Notch activation following co-
culture of MVSCs with OP9-Delta1 feeder cells for 2
weeks promoted MVSC transition to vSMC [5]. MVSCs
are resident stem cells located in the tunica media and
adventitial layers of the arterial wall and express the neural
crest cell marker Sox10, endoderm marker Sox17, glial cell
marker S100β and neural filament-medium polypeptide
(NFM) [5]. Sox10 is routinely used to identify and trace
MVSCs in blood vessels [5,15]. MVSCs can be cloned
from single cells, possess telomerase activity and can dif-
ferentiate into Schwann cells, peripheral neurons, vSMCs,
chondrocytes, adipocytes and osteoblasts [5].
The A10 and A7r5 cell lines were originally derived
from the thoracic aorta of 14-17 day old embryonic
BD1X rats and are a commonly used model of vSMC in
culture [16]. Initial characterisation of these cells sug-
gested that they were non-differentiated vSMC that dif-
fer from neonatal but bear significant resemblance to
neointimal cells [16]. The functionality of A10 and A7r5
cells and their relevance to mechanisms underlying the
contractile properties of highly differentiated vascular
smooth muscle cells is questionable. Nevertheless, these
cell lines exhibit an adult smooth muscle phenotype and
show expression and promoter activity of several highly
restricted smooth muscle cell markers [17]. Moreover, a
phenotypic transition from vascular smooth to skeletal
muscle and a detailed examination of the gene expres-
sion program associated with this transition has been re-
ported [18]. The cells also have the ability to contract by
both calcium- dependent and -independent mechanisms
[19]. On the other hand, the actin cytomatrix of these
cells shows many structural similarities to fibroblasts,
much like other smooth muscle cell types that revert to
a less differentiated phenotype in culture [1,16,17]. Des-
pite this, the cell lines are widely used by researchers
due to their apparent similarities to neointimal cells and
therefore offer an excellent model system for studying
the transcriptional regulation of vSMC markers and sig-
naling cascades involved in neointima formation [16,17].In light of the recent characterization of resident vas-
cular stem cells within vascular medial and adventitial
regions and their transition to vSMC following vascular
injury [5,20], it has been suggested that traditionally de-
fined proliferative/synthetic vSMCs, such as A10 and
A7r5 cell lines may be derived from the differentiation
of resident stem cells in culture rather than the de-
differentiation of immature/mature vSMCs [15,5]. As
both A10 and A7r5 are derived from embryonic tissue,
both cell lines were examined for their stem marker ex-
pression with a view to investigating whether these
vSMC cell lines share characteristics with resident vas-
cular stem cells in culture.
Materials and methods
Materials
All materials were of the highest purity commercially
available. Primary antibodies included: SMA (monoclo-
nal mouse anti-α-actin antibody, Sigma Cat No: A5228),
SM-MHC (monoclonal mouse anti-myosin antibody,
Sigma Cat No: clone hSM-V, M7786), (anti-MHC anti-
body [1G12], Abcam Cat No: Ab683) and (the goat poly-
clonal MYH11 Antibody (N-16) from Santa Cruz, Cat
No: SC79079 ), CNN1 (monoclonal mouse anti-calponin
antibody, Sigma Cat No: C2687), Sox10 (monoclonal
rabbit anti-Sox10 antibody, Abcam Cat No: ab155279),
Sox17 (monoclonal rabbit anti-Sox17 antibody, Millipore
Cat No: 09-038) and S100β (monoclonal rabbit anti-
S100β antibody, Millipore Cat No: 04-1054), CD44
(polyclonal rabbit anti-CD44, Abcam Cat No: Ab24504),
CD29 (monoclonal rabbit anti-CD29, Millipore Cat No:
04-1109), CD146 (monoclonal rabbit anti-CD146, Milli-
pore Cat No: 04-1147), Sca1 (rabbit polyclonal ant-Sca1,
Millipore Cat No: AB4336), c-kit (polyclonal rabbit anti-
c-Kit, Bioss Cat No: bs-10005R, polyclonal rabbit anti-c-
Kit, Santa Cruz Cat No: sc-168) and flt-1 (monoclonal
rabbit anti-Flt-1 Abcam Cat No: ab32152) and β-actin
(monoclonal mouse anti-β-actin, Sigma Cat No: A5316).
Cell culture
A10 and A7r5 cells were obtained from ATCC Rockville,
MD. Rat aortic SMC [rSMCs, R354-05a] were obtained
from Cell Applications, CA. Cells were maintained in either
Dulbecco’s Modified Eagle’s Medium (DMEM) or RPMI
1640 media supplemented with 10% foetal bovine serum
(FBS), 150 units/ml penicillin, and 150 μg/ml streptomycin
(P/S) as previously described [21]. Cells were grown at 37°C
in 5% CO2 and 95% air. Confluent cells were passaged
using 2x trypsin/0.53 mM EDTA. Gibco rat mesenchymal
stem cells (MSCs) were obtained from Life Technologies,
CA. MSC cells were maintained in growth media made up
of 50:50 minimal essential medium (α-MEM) and Ham’s
F12 supplemented with 10% MSC defined FBS, 150 unit/
ml penicillin, and 150 μg/ml streptomycin. Mesenchymal
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along adipogenic lineages and the expression of cell surface
markers indicative of MSC (i.e. CD29, CD44, CD90,
CD146).
Isolation of rat multipotent vascular stem cells [MVSCs]
MVSCs were isolated from rat aortic explants as de-
scribed previously [5]. Briefly, male Sprague Dawley
rats were first anesthetized with pentobarbital sodium
(0.1 mg/g) and then perfused with 10 mL of PBS. Arter-
ial tissues were harvested as quickly as possible and fur-
ther dissected in DMEM supplemented with 1% fetal
bovine serum (FBS). The aorta was then isolated from
the lower thoracic aorta to the upper abdominal aorta. The
endothelium was removed by scraping off the cell layer on
the luminal surface with sterile scalpel blade before the ad-
ventitia was carefully removed from media following brief
enzymatic digestion with 2.5 mg/mL of collagenase for 15
min at 37°C using forceps under a dissection microscope.
The remaining media was cut into 1-mm pieces, placed
onto the surface coated with 1% CellStart (Invitrogen) in 6-
well plates and grown in MVSC culture medium containing
DMEM with 2% chick embryo extract (MP Biomedical),
1% FBS, 1% N2 (Invitrogen), 2% B27 (Invitrogen), 100 nM
retinoic acid (Sigma-Aldrich), 50 nM 2-mercaptoethanol
(Sigma-Aldrich), 1% P/S and 20 ngml−1 bFGF (R&D
Systems) (maintenance medium). All procedures were ap-
proved by the University Animal Care Committee and were
carried out in accordance with EU guidelines for the Pro-
tection of Animals used for Scientific Purposes, (Amend-
ment) Regulations 2013 (S.I. No 434 of 2013).
Cell proliferation assays
Cells were seeded at 1 × 104 cells/well and quiesced for 48
h. The cells were then grown in DMEM supplemented
with 10% FBS over 12 days. At each time point, the cells
were washed twice in PBS and fixed in 4% paraformalde-
hyde (PFA) solution for 10 minutes at room temperature
followed by 2 washes of PBS. Following the fixation
process, cells were stained for 10 minutes in PBS contain-
ing 0.1% Triton X-100 with 30 μM DAPI. Fluorescent im-
ages were collected by an Olympus DP-50 fluorescent
microscope with the appropriate excitation and emission
spectra at 4 ×, 10 ×, 20 ×magnification before the fluores-
cent DAPI labeled nuclei were the counted automatically
using the Fiji software package [22].
Immunoblot analysis
Protein extracts (15-40 μg) were fractionated by SDS-
PAGE on 7-15% (w/v) polyacrylamide resolving gels, as
previously described [23]. Minor differences in protein
loading and transfer were normalised using a Ponceau S
stain and by measuring the constitutive β-actin protein
levels.Quantitative real-time quantitative RT-PCR
Quantitative real-time RT-PCR was performed using the
Rotor Gene (RG-3000, Corvett Research) and the SYBR
green PCR kit (Qiagen) according to the manufacturer’s
instructions. Cells were initially seeded onto 35mm cul-
ture dishes at a density of 1 × 105 cells/well in DMEM
with 10% FBS, 1% penicillin/streptomycin and quiesced
for 24 hours. Cells were then subjected to conditions of
serum and serum deprivation in DMEM with 5% FBS,
1% P/S and DMEM with 0.5% FBS, 1% P/S respectively
for 48 hours. RNA was isolated using the Maxwell™ 16
Total RNA Purification kit according to the manufac-
turer’s instructions. RNA samples were quantified and
investigated for purity using the nanodrop 2000 spectro-
photometer (Thermo Scientific). Total RNA (1-10 ng)
was then reverse transcribed and PCR amplified in a
one-step reaction containing RT mix, SYBR green mix,
and RNase free water at 55°C for 10 mins, 95°C for 5
mins, followed by 60 cycles of 95°C for 5 seconds, 60°C
for 15 seconds and subsequent melt curve analysis. Sam-
ples were run in triplicate with a no reverse transcriptase
(-RT) control. Gene expression was normalised to that
of the housekeeping gene, GAPDH.
Flow cytometry
Cells were cultured until confluency in T75 flasks and
then trypsinised in 2x trypsin/0.53 mM EDTA at 37°C.
Cells were resuspended in media, counted, and then
fixed in BD Cytofix/Cytoperm solution (BD Bioscience)
for 20 mins at 4°C. Cells were then washed in 1X BD
Perm/Wash solution (BD Bioscience) by centrifugation
at 500 g for 3 mins. Following washing, cells were resus-
pended in 1X BD Perm/Wash solution containing 1 μg
of appropriate primary antibody and incubated at 4°C
for 30 mins. Following washing, cells were resuspended
in 1X BD Perm/Wash solution containing 1 μg of appro-
priate enzyme-linked secondary antibody and incubated
at 4°C for 30 mins. Cells were then washed in BD Perm/
Wash solution and resuspended in a final volume of
500 μL of BD Perm/Wash solution.
Immunocytochemistry
Cells were seeded at a density of 1 × 104 cells/well onto
non-coated glass cover slips (20 mm) (Thermo-Scien-
tific) in 35 mm culture dishes and quiesced by serum
deprivation for 24 hours. Cover slips were sterilised in
IMS and washed twice in PBS prior to culturing. Media
was then replaced to media containing either media con-
taining 0.5% or 10% FCS and cells were cultured for a
further 48 hours. Cells were washed twice in PBS and
fixed for 15 min at room temperature (RT) with 3.7%
paraformaldehyde prepared in PBS, washed twice with
PBS, and then permeabilised by a 15 min RT exposure
to a 0.1% Triton X-100/PBS solution. The cells were
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5% BSA and 1% Tween before treatment with specific pri-
mary antibodies. Secondary antibodies were Alexa Fluor
546 goat anti-rabbit, rabbit anti-mouse and goat anti-
mouse (Invitrogen) and Alexa Fluor 488 goat anti-rabbit
(Invitrogen). Nuclei were stained with 4, 6-diamidino-2-
phenylindole (DAPI) at a concentration of 2 μg/ml in PBS
at RT for 10 minutes. Fluorescent images were collected
by an Olympus DP-50 fluorescent microscope with the
appropriate excitation and emission spectra at 4 ×, 10 ×,
20 × and 60 ×magnification. Non-specific labeling was
assessed following secondary antibody treatment.Figure 1 Vascular SMC Differentiation Marker expression. A and B. Re
in A10 and A7r5, respectively. Cells were cultured in DMEM supplemented
stained positive for (a-c) SMA (d-f) SM-MHC, and (g-i) CNN1. The nuclei of
C. Confocal immunocytochemical staining of SMC differentiation markers i
with (a-c, g-I, m-o) 5% FBS and (d-f, j-l, p-r) 0.5% FBS for 72 h before cells
SMC markers (a-f) SMA and (g-l) SM-MHC and (m-r) CNN1. Arrows designa
Scale bar, 100 nm and 250 nm. Data are representative of individual slidesConfocal microscopy
A7r5 and A10 cells were plated onto glass coverslips,
placed in six well culture plates and returned to the in-
cubator for a minimum of 24 h to allow for cell attach-
ment and spreading. Cells were fixed and permeabilised
by the addition of ice-cold acetone for 1 min. The cells
were then washed multiple times (3X) with phosphate-
buffered saline (PBS) containing 0.5% TWEEN-20 (PBS-
T); pH 7.5, and incubated for 10 min in blocking solu-
tion (5% non-fat dry milk in PBS-T). Cells were stained
for 30 min at room temperature with specific antibodies
followed by incubation with an Alexa 488-labelledpresentative immunocytofluorescence of SMC differentiation markers
medium for 3 days before immunocytochemistry was performed. Cells
were stained with DAPI. Scale bar applies to all images, 250 nM.
n A7r5 cells. Quiesced A7r5 cells and grown in DMEM supplemented
were analyzed under confocal immunofluorescence microscopy for
te myofilamentous structures. The nuclei of were stained with DAPI.
with similar results.
Kennedy et al. Vascular Cell 2014, 6:6 Page 5 of 13
http://www.vascularcell.com/content/6/1/6secondary antibody (Molecular Probes, Eugene, OR,
USA). The cells on cover slips were mounted on slides
with antifade medium (Dako). Slide preparations were
observed using a Zeiss Axio Observer. Z1 equipped with
a Zeiss 710 and ConfoCor3 laser scanning confocal head
(Carl Zeiss, Inc.). Images were analyzed using Zen 2008
software as previously described [24].
Adipocyte differentiation
Cells were seeded onto 6-well-plates at a density of
50,000 cells/well. Cells were allowed to recover from
trypsinisation for 2 days in complete medium. After re-
covery, cells were cultured in adipocyte differentiation
media for 14d (StemPro® Adipogenesis Differentiation,
Life Technologies) as according to the manufacturer’s in-
structions. Adipocyte differentiation was evaluated by
Oil Red O and HCS LipidTOX™ Green neutral lipid
staining (InVitrogen), as described by the manufacturers
protocols.
Osteoblast differentiation
Cells were seeded onto 6-well-plates at a density of 50,000
cells/well and allowed to recover from trypsinisation for 2
d in maintenance medium. After recovery, cells were cul-
tured in StemPro® Osteogenesis Differentiation Media Kit,Figure 2 Multipotent vascular stem cell (MVSC) marker expression. A
markers (a-c) SM-MHC and neural stem cell markers (d-f) Sox10, (g-i) S100
cultured in MVSC maintenance media. The nuclei of were stained with DAP
B. Representative flow cytometry analysis of MVSCs cultured in DMEM supp
Sox10, Sox17 and S100β. Open curves represent negative control samples;
SM-MHC, Sox10, Sox17 an S100β.Life Technologies) according to the manufacturer’s in-
structions. Osteoblast differentiation was evaluated using
2% Alizarin Red S stain (Sigma).
Notch inhibition
Cells were seeded at a density of 1.5 × 104 cells/well onto
non-coated glass cover slips (20 mm) in 35 mm culture
dishes and cultured for 72 hours in DMEM containing 10%
FBS and 1% P/S. Cells were then treated with either DMSO
(0.1%) or the γ − secretase inhibitor, DAPT (10 μM) for 48
hours. Cells were fixed for immunostaining as described
above. DAPT, at a stock concentration of 18 mg/ml, was di-
luted to a 10 μM working solution in DMEM containing
10% FBS and 1% P/S.
Statistics
Results are expressed as mean ± SEM. Experimental
points were performed in triplicate, with a minimum of
three independent runs. A t-test was used for compari-
son of two groups. A value of p ≤ 0.05 was considered
significant.
Results
A10 and A7r5 cells were cultured in normal DMEM
media supplemented with 10% FCS before phenotypic. Representative immunocytofluorescence of SMC differentiation
β and (j-l) Sox17 in markers rat aortic MVSCs isolated by explant and
I. Scale bar, 100 nm. Data are representative of three experiments.
lemented with 10% FBS for 10 d with antibodies against SSEA-1,
red filled curves represent samples stained with antibodies against
Figure 3 MVSC transition to vSMC following inductive
stimulation. Representative immunocytofluorescence of SMC
differentiation markers (a, b) SM-MHC, (c, d) SMA and (e, f) CNN1 in
MVSCs cultured in differentiation media (DMEM supplemented with
10% FBS) for 7 d in the absence or presence of 2 ng/ml TGF-β1 and
10 ng/ml PDGF. The nuclei stained with DAPI. Scale bar, 100 nm.
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sion, was performed. The embryonic A10 cell line had
the typical myoblast morphology when grown in culture
and was positive for SMC differentiation markers SMA,
CNN1 and SM-MHC (Figure 1A). In addition, every cell
appeared positive for each of these antigens. In contrast,
embryonic A7r5 cell line had a flat ribbon-like structure
and grew to parallel arrays of spindle shaped cells when
confluent (Figure 1B and C). Moreover, while these cells
were also positive for SMC differentiation markers
SMA, CNN1 and SM-MHC, there was a proportion of
A7r5 cells that appeared to be weakly positive for SM-
MHC and CNN1 when compared to the proportion of
SMA positive cells (Figure 1B).
Quiescence of SMCs by serum deprivation has previ-
ously been shown to drive SMC differentiation with in-
creased expression of SMA, CNN1 and SM-MHC
reported [13]. We evaluated the repercussions of serum-
deprivation on A10 and A7r5 SMC differentiation by
measuring changes in the distribution and expression of
SMC differentiation markers (SMA and CNN1) by con-
focal microscopy. In the case of A7r5 cells, there was a
notable redistribution of SMA and CNN1 filaments in
cells following serum-deprivation for 72h when compared
to serum conditions (Figure 1C). Confocal immunocyto-
fluorescence demonstrated a marked reorganization of
actin filaments under serum conditions, compared with
serum deprivation, with less filamentous staining and
greater intensity at the periphery (Figure 1C). In a similar
manner, the distribution and filamentous nature of CNN1
staining was greater in serum-deprived cells when com-
pared to serum conditions [Figure 1C]. In contrast, there
was no significant change in SM-MHC distribution
(Figure 1C). A similar profile with regard to the reorga-
nization of SMA and CNN1 filaments and their fila-
mentous nature was evident in A10 cells in response to
serum deprivation (data not shown).
Previous studies had suggested that SM-MHC negative
(SM-MHC−) cells can be defined as synthetic and/or prolif-
erative SMCs in culture [4,14]. More recent studies now
suggest that SM-MHC− cells derived from the vascular
media by explant culture are multipotent vascular stem cells
[MVSCs] capable of transition to several different non-
vascular lineages [5,15]. Therefore, MVSCs isolated from rat
aortic explants as described previously [5], served as our
control MVSC population. Microscopic analysis confirmed
that the MVSCs were immunocytochemically negative for
SM-MHC, but positive for neural stem cell markers Sox10,
Sox17 and S100β (Figure 2A). The MVSCs also expressed
several MSC-like phenotypic markers CD44 and CD29 in
culture but were negative for CD146 [data not shown].
FACS analysis confirmed that the MVSCs were positive for
Sox10, Sox17 and S100β (Figure 2B) but negative for the
stage specific embryonic antigen (SSEA-1) marker.While the MVSCs were immunocytochemically Sox10+
and SM-MHC−, they expressed SMA in both maintenance
and DMEM supplemented media [data not shown]. More-
over, the expression of SMC differentiation markers, SM-
MHC and CNN1, was greatly enhanced following culture
of these cells for 7 d in DMEM media supplemented with
10% FBS (differentiation media) in the presence of the in-
ductive stimuli, TGF-β1 (2ng/ml) and PDGF (10ng/ml)
when compared to differentiation media over the same
time period (Figure 3). FACS analysis of MVSCs further
confirmed that these cells remain Sox10+ and Sox17+
positive while concomitantly expressing SM-MHC after 7
d [data not shown].
We therefore used anti-Sox10 and anti-SM-MHC anti-
bodies to investigate the presence of ‘MVSC-like’ posi-
tive cells (SM-MHC− Sox10+) in each of the embryonic
SMC cell lines. Using immunocytochemistry, we found
no evidence for SM-MHC− cells present in A10 cultures
Kennedy et al. Vascular Cell 2014, 6:6 Page 7 of 13
http://www.vascularcell.com/content/6/1/6(Figure 4). In contrast, all of the cells stained strongly
for SM-MHC+ and uniformly expressed markers includ-
ing neural crest cell markers Sox10 and the endoderm
marker Sox17 (Figure 4A). These cells were also positive
for stem cell antigen, Sca1+. Subsequent FACS analysis
of SMC differentiation and MVSC marker expression in
these A10 cells confirmed quantitatively that >90% of
the cells were MHC+ Sox10+, Sox17+, S100β+ and Sca1+
(Figure 4B).
A7r5 cells were also positive SM-MHC, albeit not as
robust as A10 cells, and were SM-MHC+ by FACS ana-
lysis. A7r5 were also positive for neural stem cell
markers Sox10+, Sox17+ and S100β+ (Figure 5A). These
cells were also positive for Sca1+ (Figure 5A). Subse-
quent FACS analysis confirmed quantitatively that >90%
of the cells were MHC+ Sox10+, Sox17+, S100β+ and
Sca1+ (Figure 5B). Parallel Western blot analysis of SMC
differentiation and MVSC stem cell marker expression
confirmed that both A10 and A7r5 cells express SMA,
CNN1 and the MVSCs markers. However, the SM-MHC
isoforms for A10 and A7r5 were different. The A10 cells
expressed Sm2 whereas the A7r5 cells predominantlyFigure 4 MVSC marker expression in A10 cells. A. Representative immu
SM-MHC (g-i) Sox17 and (j-l) Sca1 in quiesced cells grown in normal DMEM
immunocytochemistry (d-i) confocal microscopy. Arrows show localisation
with DAPI. Scale bar applies to all images, 250 nm except (a-c, 100 nm). Da
cytometry analysis of A10 cells with antibodies against SM-MHC, Sox10, So
red-filled curves represent samples stained with antibodies against SM-MHCexpressed non-muscle MHC, as previously reported
[16,17]. The MVSCs derived from rat aorta expressed
Sm1 [Figure 6A]. In addition, the A10 and A7r5 cells both
expressed c-kit and Flt-1 by immunocytochemistry and by
FACS analysis (Figure 6B and C). However, unlike A10
and A7r5, MVSC and rSMCs were both positive for c-kit
but weakly expressed flt-1 (Figure 6B and C).
To further investigate the expression of MVSC markers
within the A10 and A7r5 cell lines, we carried out gene
expression analysis of SMC differentiation and MVSC
marker expression by real-time qRT-PCR. The repercus-
sions of serum deprivation on SMC differentiation and
MVSC marker expression in A7r5 cells were evaluated by
measuring changes in SMC differentiation [SMA, Sm1,
Sm2 and CNN1] and neural crest stem cell [Sox10, Sox17,
S100β] marker gene expression. Serum stimulation re-
sulted in a significant increase in Sox10, Sox17 and S100β
for A7r5 cells with a concomitant decrease in the SMC
differentiation markers Sm1 and CNN1 while SMA and
Sm2 levels increased. The increase in marker expression
was greatest for S100β (Figure 7A). In contrast, serum
stimulation increased A10 SMC differentiation markernocytofluorescence of neural stem cell markers (a-c) Sox10, (d-f)
media supplemented with FBS for 3 d and visualised by (a-c)
of Sox10 and Sox17 primarily to the nucleus. The nuclei were stained
ta are representative of three individual slides. B. Representative flow
x17, S100β and Sca1. Open curves represent negative control samples;
, Sox10, Sox17, S100β and Sca1.
Figure 5 MVSC marker expression in A7r5 cells. A. Representative immunocytofluorescence of neural stem cell markers (a-c) Sox10, (d-f)
SM-MHC (g-i) Sox17 and (j-l) Sca1 in quiesced cells grown in normal DMEM media supplemented with FBS for 3 d and visualised by (a-c)
immunocytochemistry (d-i) confocal microscopy. Arrows show localisation of Sox10 and Sox17 primarily to the nucleus. The nuclei were stained
with DAPI. Scale bar applies to all images, 250 nm except (a-c, 100 nm). Data are representative of three individual slides. B. Representative flow
cytometry analysis of A7r5 cells with antibodies against SM-MHC, Sox10, Sox17, S100β and Sca1. Open curves represent negative control samples;
red-filled curves represent samples stained with antibodies against SM-MHC, Sox10, Sox17, S100β and Sca1.
Kennedy et al. Vascular Cell 2014, 6:6 Page 8 of 13
http://www.vascularcell.com/content/6/1/6expression with a concomitant increase in neural crest cell
markers Sox10, Sox17 and S100β expression in these cells
(Figure 7B). In addition, the growth of MVSCs lag behind
the A10 and A7r5 in the early growth phase, but recover
by day 12 [Figure 7C].
Expression of neural stem cell markers [Sox10, Sox17
and S100β] suggests that these embryonic SMC cell lines
may retain some stem cell properties. To assess whether
A10 and A7r5 cell lines were multipotent, we determined
their capability of becoming adipocytes following treat-
ment with specific induction media. Adipocyte differenti-
ation was determined by both oil red staining and
lipidTOX™ fluorescent staining after a 14 d treatment with
the induction media. Rat mesenchymal stem cells (rMSCs)
and rat aortic derived MVSCs (rMVSCs) were also treated
with the same adipocyte induction media and served as
positive controls (Figure 8). Bovine aortic endothelial cells
served as a negative control (data not shown). Both rat
MSCs and MVSCs were capable of differentiation to adi-
pocytes after 14d treatment since the number of Oil Red
O positive and LipidTOX™ positive cells was significantly
increased (Figure 8). In parallel studies, rat MSCs and
MVSCs were also capable of differentiation to osteoblasts
after 14 d inductive treatment when analyzed with Ali-
zarin Red S [data not shown]. While both A10 and A7r5
cells did retain some Oil Red O stain and LipidTOX™fluorescent stain following treatment with inductive differ-
entiation media, the number of positive cells was signifi-
cantly less than MVSCs or the MSCs (Figure 8).
As Notch is a critical arbiter of mesenchymal stem cell
(MSC) transition to vascular lineages [25,26] and since
MVSC transition to a MSC-like intermediate occurs en
route to their differentiation to vSMC [5], we examined the
effect of Notch inhibition on A10 and A7r5 differentiation.
Notch 1 receptors, like in rat [27] and human vSMC [28],
were present on these cells [data not shown]. We investi-
gated if Notch inhibition following treatment with a γ-
secretase inhibitor (DAPT), could force these cells to adopt
a more contractile phenotype and decrease MVSC marker
expression by monitoring SM-MHC and Sox10 expression
using immunocytochemistry and qRT-PCR. We found that
treatment of both cell types with DAPT did not significantly
alter the percentage of Sox10+, despite a change in cell num-
ber following Notch inhibition (Figure 9A, B). Moreover,
Notch inhibition significantly enhanced MVSC marker ex-
pression [Sox10, Sox17 and S100β] in both cell types while
preferentially increasing Sm2 and SMA in A7r5 but SMA,
Sm1, Sm2, SMO and CNN1 in A10 cells (Figure 9A, B).
Discussion
The characteristics of vSMCs and their modulation in
culture have long been the subject of investigation
Figure 6 SMC and stem cell marker expression in A10, A7r5 and MVSCs. A. Representative immunoblots for SMC differentiation markers
(SM-MHC, SMA and CNN1) and neural stem cell markers (Sox10, Sox17, S100β in lysates from quiesced cells grown in normal DMEM media
supplemented with FBS for 3 d. The levels of SM-MHC (Sm1, Sm2 and non-muscle MHC), SMA, CNN1, Sox10, Sox17 and S100β were determined
using specific antisera against these antigens. Data are representative of blots with similar results. Equal loading was confirmed by Ponceau S
staining of the membranes and by measuring the constitutive β-actin gene. B. Immunocytochemical staining of c-Kit and Flt-1 in MVSCs, rSMC,
A7r5 and A10 cells. Quiesced cells were grown in normal DMEM media supplemented with FBS for 3 d before the cells were stained for c-kit and
flt-1. C. Representative flow cytometry analysis of Flt-1 and c-Kit in A7r5, A10 and MVSCs using antibodies against Flt-1 and c-Kit. Open curves
represent negative control samples; red filled curves represent samples stained with antibodies.
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up a new debate about the phenotype and origin of
‘modulated’ de-differentiated, neointimal cells in vivo
and in vitro [15,30-32]. Accordingly, we performed a
comprehensive analysis of SMC differentiation and
MVSC marker profile, growth properties and multipo-
tency capacity for embryonic A7r5 and A10 SMC cells
in culture.
The embryonic cell lines A7r5 and A10, and adult aor-
tic SMC cells have all been shown to express SMC dif-
ferentiation markers including SMA, CNN1, SM22,
tropoelastin and to a lesser extent, SM-MHC [17,33].
Interestingly, A10 and to some extent A7r5 resembled
the epithelioid phenotype similar to that of the SMC
population (“pup cells”) cultured from the intimal thick-
ening 15 days after endothelial injury [34]. A10 and
A7r5 were also similar to cloned newborn rat SMC in
that they continue to express SMA and SM-MHC in cul-
ture [33]. Both cell lines express abundant SMA and
CNN1 with similar growth characteristics. Moreover, in
agreement with previous studies of cultured SMC, the fila-
mentous profile for SMA and CNN1 was enhanced under
conditions of serum deprivation [12]. However, theexpression of SM-MHC was noticeably different [17,18].
In the case of A10, the cells predominantly expressed Sm2
with some myofilamentous structures evident under both
serum and serum-deprived conditions. In contrast, A7r5
cells predominantly expressed non-muscle SM-MHC with
no discernible myofilaments. However, A7r5 have several
characteristics in common with neointimal cells including
the expression of SMA and non-muscle MHC [16].
The stem cell origin of vSMCs within vascular lesions
has been controversial [30-32]. Initial studies in canine
carotid arteries suggested that neointimal modulated
proliferative SMC were not derived from differentiated
cells but instead formed by a myosin negative type 2
medial SMC cell [14]. Since then, several major types of
resident SMC-related vascular progenitors have been
identified within the tunica media. These include mesen-
chymal stem cell (MSC)-like cells, a side population of
Sca1+ progenitors and multipotent vascular stem cells
(MVSCs). MSC-like cells express CD29 and CD44 and
have multilineage potential for osteogenic and chondro-
genic differentiation but importantly, not for adipogenic
differentiation [35]. MVSCs on the other hand express
neural stem cell markers including Sox17, Sox10 and
Figure 7 Quantitative qRT-PCR of neural stem cell marker and SMC differentiation marker mRNA levels. A and B. Quiesced A7r5 and A10
cells were cultured in DMEM media supplemented with 5% FBS and 0.5% FBS for 3 d before relative gene expression of SMC markers [SMA, MHC
and CNN1] and neural stem cell MVSC markers [Sox10, Sox17 and S100β] were determined by qRT-PCR. GAPDH was used to normalize gene
expression. Data are mean ± SEM and are representative of three independent wells, *p < 0.01 when compared to 0.5% FCS. C. Representative
growth curves for A10, A7r5 and MVSCs grown for 12 d in their respective media. Cell number was quantified by counting DAPI stained nuclei.
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ferentiate into neural cells and MSC-like cells that subse-
quently differentiate and transition to SMCs. Sca-1+
progenitors within the adventitia or media can differentiate
into SMCs [29] and contribute to atherosclerosis of vein
grafts in ApoE-deficient mice [20,36]. Further CD146+ peri-
vascular MSC-like cells demonstrate osteogenic, chondro-
genic and adipogenic potentials [37].
Importantly, lineage tracing has not resolved whether
adult rat SMCs are derived from differentiated medial
SMCs [9], MVSCs [5], or both. Elegant epigeneticFigure 8 Multipotent potential of MSC, MVSC, A10 and A7r5 cells in v
MVSCs and A10 and A7r5 cells following treatment of cells with adipocyte
determined by both Oil Red O and LipidTOX™ staining of lipid droplets. Dasignature studies tracking histone modifications of the
Sm2 (MYH11) locus both in vitro and in vivo further
suggest that SMCs both in culture and following injury
are derived from mature differentiated SMC [11,38].
While the passage number, confluency and method of
isolation for these SMCs in vitro may impact on these
findings, it is clear that epigenetic signature studies are
most useful when cells have lost a particular phenotype
(and hence specific marker) or changed to multiple phe-
notypes. However, this is not the case in this study as
A10 cells express both MVSC and SMC markers (Sm2itro. Representative images of adipocyte differentiation of MSCs,
differentiation media for 14 d. Adipocyte differentiation was
ta are representative of three independent experiments.
Figure 9 The effects of Notch inhibition with DAPT on Sox10 expression in A7r5 and A10 cells. A. Quiesced A10 cells were grown
in media containing 10% FBS supplemented with or without 10 μM DAPT for 3 d before the expression of Sox10 was determined by
immunocytochemistry. B. Relative gene expression of SMC markers [(SMA, MHC, CNN1 and smoothelin (SMO)] and neural stem cell MVSC
markers [Sox10, Sox17 and S100β)] in A10 and A7r5 cells was determined by qRT-PCR. GAPDH was used to normalize gene expression. Data are
mean ± SEM and are representative of three independent wells, *p < 0.01 when compared to 0.5% FCS.
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grees. Additionally, as MVSCs acquire SM-MHC (Sm2)
expression when they are cultured in DMEM 10% FBS
media (and not maintenance media [11,38]), or induced
using TGF-β1, it is possible that the same histone modi-
fications at the SM-MHC locus are apparent for MVSCs
when acquiring SM-MHC expression.
The possibility also exists that de-differentiated SMC
derived from differentiated medial SMC may revert back
to multipotent/pluripotent stem cells and express neural
stem cell markers. Indeed, recent studies have suggested
that under certain circumstances, cultured rat SMC can
be induced to osteogenic and skeletal muscle lineages
[39,40] further supporting a plasticity and stemness as-
sociated with SMC in culture that may involve acquiring
neural stem cell markers. Indeed somatic cells in general
can respond to stimulus-triggered acquisition of pluripo-
tency [STAP] [41,42]. Our study clearly demonstrates
that both A10 and A7r5 uniformly express the neural
stem cell markers [Sox10, Sox17 and S100β] typical of
MVSCs [5] but also express Sca1, which is associated
with perivascular adventitial progenitor stems cells [20].
They also concomitantly express SMC differentiation
markers, SMA and CNN1 and Sm2 and non-muscleMHC, respectively [42]. Our data also suggest that both
A10 and A7r5 cells also maintain some multipotent cap-
abilities as they mimic MVSCs and MSC’s in their ability
to differentiate to adipocytes (and osteoblasts), albeit less
robustly, following inductive stimulation. In addition,
DAPT which inhibits Notch signalling and is a critical
component during MSC to SMC transition [26,43,44]
significantly alters both MVSC and SMC differentiation
markers in both cell lines promoting neural stem cell
phenotypes while increasing SMC differentiation. We
have previously shown that Notch promotes SMC de-
differentiation in vitro [28]. It is also worth noting that
mechanistically, Sox17 acts upstream of the Notch sys-
tem and downstream of the canonical Wnt system in or-
chestrating arterial specification during development
and may thus be critical for MVSC transition to SMC
in vitro [45].
The reason(s) for the appearance of MVSC neural
stem cell markers in SMC cell lines in culture remain(s)
unknown. One possibility is that both cell lines originate
from MVSCs where the SMCs from MVSCs outgrow
the de-differentiated SMC and eventually dominate the
cultures [15]. In this regard, the growth curves for
MVSCs, A10 and A7r5 suggest that MVSCs lag behind
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cover to comparable growth rates by day 12. Notwith-
standing the controversy as to whether neointimal SMC
following injury are derived from resident stem cells or
de-differentiated SMCs, or even both, there is no con-
troversy surrounding the phenotype of medial SMC in
normal vessels in situ before culture. In this context,
SMC prepared by explant culture from SM-MHC-Cre/
LoxP-enhanced green fluorescence protein (EGFP) mice
are predominantly immunocytochemically eGFP nega-
tive (and hence SM-MHC negative) but Sox10, Sox17
and S100β positive, yet acquire eGFP (SM-MHC) when
sub-cultured in vitro or activated by a Notch ligand or
TGF-β1 in vitro [5]. In contrast, medial vSMC before
enzymatic dispersal are predominantly eGFP (SM-MHC)
positive and express little to no Sox10, Sox17 or S100β
in situ. This profile is maintained when cells are enzy-
matically dispersed and cultured at P0 [15]. Over time,
these cells are widely thought to become ‘modulated’
and reduce their expression of SMC differentiation
markers, in particular SM-MHC, when compared to
cells in situ or P0 in culture. Our data for rat aortic de-
rived MVSCs suggests that cells maintained in stem cell
maintenance media at early passage are predominantly
SM-MHC− (Sm2) negative but positive for Sm1, Sox10+,
Sox17+ and S100β+. Importantly, they can transition to
adipocytes (and osteoblasts) following specific inductive
stimulation and enhance their expression of SMC differ-
entiation markers when grown in non-MVSC stem cell
media (DMEM+ 10% FCS or TGF-β1).
The presence of stem cell antigen, Sca1+ on both em-
bryonic SMC lines suggest that these cells also exhibit
some perivascular markers. Vascular Sca1+ is associated
with adventitial progenitors and a side population of
medial progenitors that have the capacity of differentiate
to SMC [6,20,29,36]. While MVSCs are reported to be
initially Sca1− negative [5], the relationship, if any be-
tween MVSCs in the media and Sca1+ progenitors in the
adventitia remains unknown. In addition, the presence
of c-kit and Flt-1 positive cells within the A10, A7r5 and
MVSC population is characteristic of SMCs derived
from large arteries of older vessels and may suggest a
similar stem cell origin [46].
In conclusion, the expression of neural stem cell
markers in A10 and A7r5 suggests that these SMCs may
represent MVSC-derived SMC, de-differentiated SMC
or both. In addition, their expression of perivascular
Sca1 suggests that these cells may also have adventitial
mesoderm origins. Both cell lines should now prove use-
ful in determining the functionality of SMC in disease as
they clearly resemble neo-intimal SMC known to be de-
rived from MVSC following vascular injury [5]. Further
single cell tracing experiments will be required to delin-
eate the precise relationship between these two origins.Competing interests
On behalf of all authors, the corresponding author states that there is no
competing interests.
Authors’ contributions
EK, RH, CG and EM carried out the cell isolation, characterization and marker
expression studies on each cell line. EK, CG, CM carried out the qRT-PCR
analysis. EK, EM and SG performed the FACS analysis. EM, LEC and CEL carried out
the confocal microscopic analysis. SG, DM EMR and PAC participated in the
supervision of experiments and data analysis. EMR and PAC participated in the
design, drafting and writing of manuscript. All authors have read and approved
the final manuscript.
Acknowledgements
This study was supported in part by funds from Science Foundation Ireland
(SFI-11/PI/1128 to P.A. Cahill), the National Institutes of Health (R00HL095650
to D. Morrow and R21AA020365 to E.M. Redmond).
Author details
1Vascular Biology and Therapeutics Laboratory, School of Biotechnology
Faculty of Science and Health, Dublin City University, Dublin 9, Ireland.
2Immunomodulation Research Group, School of Biotechnology Faculty of
Science and Health, Dublin City University, Dublin 9, Ireland. 3Department of
Surgery, University of Rochester Medical Center, Rochester, NY 14642, USA.
Received: 5 December 2013 Accepted: 28 February 2014
Published: 15 March 2014
References
1. Chamley-Campbell J, Campbell GR, Ross R: The smooth muscle cell in
culture. Physiol Rev 1979, 59:1–61.
2. Orlandi A, Ehrlich HP, Ropraz P, Spagnoli LG, Gabbiani G: Rat aortic smooth
muscle cells isolated from different layers and at different times after
endothelial denudation show distinct biological features in vitro.
Arterioscler Thromb 1994, 14:982–989.
3. Hao H, Gabbiani G, Bochaton-Piallat M-L: Arterial smooth muscle cell
heterogeneity: implications for atherosclerosis and restenosis
development. Arterioscler Thromb Vasc Biol 2003, 23:1510–1520.
4. Churchman AT, Siow RCM: Isolation, culture and characterisation of
vascular smooth muscle cells. Methods Mol Biol 2009, 467:127–138.
5. Tang Z, Wang A, Yuan F, Yan Z, Liu B, Chu JS, Helms JA, Li S: Differentiation
of multipotent vascular stem cells contributes to vascular diseases. Nat
Commun 2012, 3:875.
6. Torsney E, Xu Q: Resident vascular progenitor cells. J Mol Cell Cardiol 2011,
50:304–311.
7. Xu Q: The role of stem cells in vein graft remodelling. Biochem Soc Trans
2007, 35:895.
8. Nguyen AT, Gomez D, Bell RD, Campbell JH, Clowes AW, Gabbiani G,
Giachelli CM, Parmacek MS, Raines EW, Rusch NJ, Speer MY, Sturek M,
Thyberg J, Towler DA, Weiser-Evans MC, Yan C, Miano JM, Owens GK:
Smooth muscle cell plasticity: fact or fiction? Circ Res 2013, 112:17–22.
9. Nemenoff RA, Horita H, Ostriker AC, Furgeson SB, Simpson PA, VanPutten V,
Crossno J, Offermanns S, Weiser-Evans MCM: SDF-1α induction in mature
smooth muscle cells by inactivation of PTEN is a critical mediator of
exacerbated injury-induced neointima formation. Arterioscler Thromb
Vasc Biol 2011, 31:1300–1308.
10. Owens GK, Kumar MS, Wamhoff BR: Molecular regulation of vascular
smooth muscle cell differentiation in development and disease. Physiol
Rev 2004, 84:767–801.
11. Gomez D, Owens GK: Smooth muscle cell phenotypic switching in
atherosclerosis. Cardiovasc Res 2012, 95:156–164.
12. Li S, Sims S, Jiao Y, Chow LH, Pickering JG: Evidence from a novel human
cell clone that adult vascular smooth muscle cells can convert reversibly
between noncontractile and contractile phenotypes. Circ Res 1999,
85:338–348.
13. Su B, Mitra S, Gregg H, Flavahan S, Chotani MA, Clark KR,
Goldschmidt-Clermont PJ, Flavahan NA: Redox regulation of vascular
smooth muscle cell differentiation. Circ Res 2001, 89:39–46.
14. Holifield B, Helgason T, Jemelka S, Taylor A, Navran S, Allen J, Seidel C:
Differentiated vascular myocytes: are they involved in neointimal
formation? J Clin Invest 1996, 97:814–825.
Kennedy et al. Vascular Cell 2014, 6:6 Page 13 of 13
http://www.vascularcell.com/content/6/1/615. Tang Z, Wang A, Wang D, Li S: Smooth muscle cells: to be or not to be?
Response to Nguyen et al. Circ Res 2013, 112:23–26.
16. Rao RS, Miano JM, Olson EN, Seidel CL: The A10 cell line: a model for
neonatal, neointimal, or differentiated vascular smooth muscle cells?
Cardiovasc Res 1997, 36:118–126.
17. Firulli AB, Han D, Kelly-Roloff L, Koteliansky VE, Schwartz SM, Olson EN,
Miano JM: A comparative molecular analysis of four rat smooth muscle
cell lines. In Vitro Cell Dev Biol Anim 1998, 34:217–226.
18. Graves DC, Yablonka-Reuveni Z: Vascular smooth muscle cells spontaneously
adopt a skeletal muscle phenotype: a unique Myf5(-)/MyoD(+) myogenic
program. J Histochem Cytochem 2000, 48:1173–1193.
19. Nakajima S, Fujimoto M, Ueda M: Spatial changes of [Ca2+]i and
contraction caused by phorbol esters in vascular smooth muscle cells.
Am J Physiol 1993, 265:C1138–C1145.
20. Hu Y, Zhang Z, Torsney E, Afzal AR, Davison F, Metzler B, Xu Q: Abundant
progenitor cells in the adventitia contribute to atherosclerosis of vein
grafts in ApoE-deficient mice. J Clin Invest 2004, 113:1258–1265.
21. Cappadona C, Redmond EM, Theodorakis NG, McKillop IH, Hendrickson R,
Chhabra A, Sitzmann JV, Cahill PA: Phenotype dictates the growth
response of vascular smooth muscle cells to pulse pressure in vitro.
Exp Cell Res 1999, 250:174–186.
22. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T,
Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V,
Eliceiri K, Tomancak P, Cardona A: Fiji: an open-source platform for
biological-image analysis. Nat Meth 2012, 9:676–682.
23. Gao W, Ferguson G, Connell P, Walshe T, Murphy R, Birney YA, O’Brien C,
Cahill PA: High glucose concentrations alter hypoxia-induced control
of vascular smooth muscle cell growth via a HIF-1alpha-dependent
pathway. J Mol Cell Cardiol 2007, 42:609–619.
24. McEntee G, Minguzzi S, O’Brien K, Ben Larbi N, Loscher C, O’Fágáin C,
Parle-McDermott A: The former annotated human pseudogene dihydrofolate
reductase-like 1 (DHFRL1) is expressed and functional. Proc Natl Acad Sci
USA 2011, 108:15157–15162.
25. Kurpinski K, Lam H, Chu J, Wang A, Kim A, Tsay E, Agrawal S, Schaffer DV, Li
S: Transforming growth factor-beta and notch signaling mediate stem
cell differentiation into smooth muscle cells. Stem Cells 2010, 28:734–742.
26. Doi H, Iso T, Shiba Y, Sato H, Yamazaki M, Oyama Y, Akiyama H, Tanaka T,
Tomita T, Arai M, Takahashi M, Ikeda U, Kurabayashi M: Notch signaling
regulates the differentiation of bone marrow-derived cells into smooth
muscle-like cells during arterial lesion formation. Biochem Biophys Res
Commun 2009, 381:654–659.
27. Sweeney C, Morrow D, Birney YA, Coyle S, Hennessy C, Scheller A, Cummins
PM, Walls D, Redmond EM, Cahill PA: Notch 1 and 3 receptor signaling
modulates vascular smooth muscle cell growth, apoptosis, and migration
via a CBF-1/RBP-Jk dependent pathway. FASEB J 2004, 18:1421–1423.
28. Morrow D, Scheller A, Birney YA, Sweeney C, Guha S, Cummins PM, Murphy
R, Walls D, Redmond EM, Cahill PA: Notch-mediated CBF-1/RBP-J{kappa}-
dependent regulation of human vascular smooth muscle cell phenotype
in vitro. Am J Physiol Cell Physiol 2005, 289:C1188–96.
29. Sainz J, Haj Zen Al A, Caligiuri G, Demerens C, Urbain D, Lemitre M, Lafont
A: Isolation of “side population” progenitor cells from healthy arteries of
adult mice. Arterioscler Thromb Vasc Biol 2006, 26:281–286.
30. Yu H, Stoneman V, Clarke M, Figg N, Xin H-B, Kotlikoff M, Littlewood T,
Bennett M: Bone marrow-derived smooth muscle-like cells are infrequent
in advanced primary atherosclerotic plaques but promote atherosclerosis.
Arterioscler Thromb Vasc Biol 2011, 31:1291–1299.
31. Albiero M, Menegazzo L, Fadini GP: Circulating smooth muscle
progenitors and atherosclerosis. Trends Cardiovasc Med 2010, 20:133–140.
32. Orlandi A, Bennett M: Progenitor cell-derived smooth muscle cells in
vascular disease. Biochem Pharmacol 2010, 79:1706–1713.
33. Bochaton-Piallat ML, Gabbiani F, Ropraz P, Gabbiani G: Cultured aortic
smooth muscle cells from newborn and adult rats show distinct
cytoskeletal features. Differentiation 1992, 49:175–185.
34. Bochaton-Piallat ML, Ropraz P, Gabbiani F, Gabbiani G: Phenotypic
heterogeneity of rat arterial smooth muscle cell clones. Implications for
the development of experimental intimal thickening. Arterioscler Thromb
Vasc Biol 1996, 16:815–820.
35. Tintut Y, Alfonso Z, Saini T, Radcliff K, Watson K, Boström K, Demer LL:
Multilineage potential of cells from the artery wall. Circulation 2003,
108:2505–2510.
36. Xu Q: Stem cells and transplant arteriosclerosis. Circ Res 2008, 102:1011–1024.37. Crisan M, Yap S, Casteilla L, Chen C-W, Corselli M, Park TS, Andriolo G,
Sun B, Zheng B, Zhang L, Norotte C, Teng P-N, Traas J, Schugar R, Deasy
BM, Badylak S, Buhring H-J, Giacobino J-P, Lazzari L, Huard J, Péault B:
A perivascular origin for mesenchymal stem cells in multiple human
organs. Cell Stem Cell 2008, 3:301–313.
38. Gomez D, Shankman LS, Nguyen AT, Owens GK: Detection of histone
modifications at specific gene loci in single cells in histological sections.
Nat Methods 2013, 10:171–177.
39. Ciceri P, Volpi E, Brenna I, Arnaboldi L, Neri L, Brancaccio D, Cozzolino M:
Combined effects of ascorbic acid and phosphate on rat VSMC
osteoblastic differentiation. Nephrol Dial Transplant 2012, 27:122–127.
40. Liao X-B, Zhang Z-Y, Yuan K, Liu Y, Feng X, Cui R-R, Hu Y-R, Yuan Z-S, Gu L,
Li S-J, Mao D-A, Lu Q, Zhou X-M, de Jesus Perez VA, Yuan L-Q: MiR-133a
modulates osteogenic differentiation of vascular smooth muscle cells.
Endocrinology 2013, 154:3344–3352.
41. Obokata H, Sasai Y, Niwa H, Kadota M, Andrabi M, Takata N, Tokoro M,
Terashita Y, Yonemura S, Vacanti CA, Wakayama T: Bidirectional
developmental potential in reprogrammed cells with acquired
pluripotency. Nature 2014, 505:676–680.
42. Obokata H, Wakayama T, Sasai Y, Kojima K, Vacanti MP, Niwa H, Yamato M,
Vacanti CA: Stimulus-triggered fate conversion of somatic cells into
pluripotency. Nature 2014, 505:641–647.
43. Yamamizu K, Matsunaga T, Uosaki H, Fukushima H, Katayama S,
Hiraoka-Kanie M, Mitani K, Yamashita JK: Convergence of Notch and beta-
catenin signaling induces arterial fate in vascular progenitors. J Cell Biol
2010, 189:325–338.
44. Kane NM, Xiao Q, Baker AH, Luo Z, Xu Q, Emanueli C: Pluripotent stem cell
differentiation into vascular cells: a novel technology with promises for
vascular re(generation). Pharmacol Ther 2011, 129:29–49.
45. Corada M, Orsenigo F, Morini MF, Pitulescu ME, Bhat G, Nyqvist D, Breviario F,
Conti V, Briot A, Iruela-Arispe ML, Adams RH, Dejana E: Sox17 is indispensable
for acquisition and maintenance of arterial identity. Nat Commun 2013, 4:2609.
46. Ferlosio A, Arcuri G, Doldo E, Scioli MG, De Falco S, Spagnoli LG, Orlandi A:
Age-related increase of stem marker expression influences vascular
smooth muscle cell properties. Atherosclerosis 2012, 224:51–57.
doi:10.1186/2045-824X-6-6
Cite this article as: Kennedy et al.: Embryonic rat vascular smooth muscle
cells revisited - a model for neonatal, neointimal SMC or differentiated
vascular stem cells? Vascular Cell 2014 6:6.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
